Jan. 7, 2022 – “It’s understandable that it’s taken a while to get past the stigma, but … I think within the next year, we’re going to see more federal funding and less of a hesitation,” Johnson says. In 2021, even the director of the National Institutes of Health Francis Collins made headlines for praising psychedelics’ potential as a therapeutic treatment option. “Expect more of that flavor at the NIH, expect less risk aversion,” says Johnson, saying it’s shifted from being viewed as radical to a worthy avenue to explore given the promising evidence in treating depression and substance use disorders, especially in the context of a suicide and drug overdose epidemic.  


[ninja-popup ID=12216]